Literature DB >> 26932147

The Aurora kinase inhibitors in cancer research and therapy.

Jonas Cicenas1,2,3.   

Abstract

Compounds that affect enzymatic function of kinases are valuable for the understanding of the complex biochemical processes in cells. Aurora kinases (AURKs) play a key role in the control of the mitosis. These kinases are frequently deregulated in different human cancers: overexpression, amplifications, translocations and deletions were reported in many cancer cell lines as well as patient tissues. These findings steered a rigorous hunt for small-molecule AURK inhibitors not only for research purposes as well as for therapeutic uses. In this review, we describe a number of AURK inhibitors and their use in cancer research and/or therapy. We hope to assist researchers and clinicians in deciding which inhibitor is most appropriate for their specific purpose. The review will also provide a broad overview of the clinical studies performed with some of these inhibitors (if such studies have been performed).

Entities:  

Keywords:  Aurora kinases; Cancer; Cell cycle; Protein kinases; Small-molecule inhibitors

Mesh:

Substances:

Year:  2016        PMID: 26932147     DOI: 10.1007/s00432-016-2136-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  161 in total

1.  Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Authors:  Jodi A Muscal; Kathleen A Scorsone; Linna Zhang; Jeffrey A Ecsedy; Stacey L Berg
Journal:  Invest New Drugs       Date:  2012-06-06       Impact factor: 3.850

2.  Aurora-C kinase supports mitotic progression in the absence of Aurora-B.

Authors:  Scott D Slattery; Michael A Mancini; Bill R Brinkley; Rebecca M Hall
Journal:  Cell Cycle       Date:  2009-09-21       Impact factor: 4.534

3.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.

Authors:  Sofie Svensson; Karin Jirström; Lisa Rydén; Göran Roos; Stefan Emdin; Michael C Ostrowski; Göran Landberg
Journal:  Oncogene       Date:  2005-06-23       Impact factor: 9.867

4.  ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.

Authors:  Liya Zhang; Shulan Zhang
Journal:  J Obstet Gynaecol Res       Date:  2010-12-15       Impact factor: 1.730

5.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Authors:  Arijit Chakravarty; Vaishali Shinde; Josep Tabernero; Andres Cervantes; Roger B Cohen; E Claire Dees; Howard Burris; Jeffrey R Infante; Teresa Macarulla; Elena Elez; Jordi Andreu; Edith Rodriguez-Braun; Susana Rosello; Margaret von Mehren; Neal J Meropol; Corey J Langer; Bert ONeil; Douglas Bowman; Mengkun Zhang; Hadi Danaee; Laura Faron-Yowe; Gary Gray; Hua Liu; Jodi Pappas; Lee Silverman; Chris Simpson; Bradley Stringer; Stephen Tirrell; Ole Petter Veiby; Karthik Venkatakrishnan; Katherine Galvin; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Cancer Res       Date:  2010-12-10       Impact factor: 12.701

6.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

8.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

9.  Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.

Authors:  Altaf A Dar; Abbes Belkhiri; Jeffrey Ecsedy; Alexander Zaika; Wael El-Rifai
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

10.  Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

Authors:  Kelly Anderson; Zhihong Lai; Octerloney B McDonald; J Darren Stuart; Eldridge N Nartey; Mary Ann Hardwicke; Ken Newlander; Dashyant Dhanak; Jerry Adams; Denis Patrick; Robert A Copeland; Peter J Tummino; Jingsong Yang
Journal:  Biochem J       Date:  2009-05-13       Impact factor: 3.857

View more
  21 in total

Review 1.  KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.

Authors:  Jonas Cicenas; Linas Tamosaitis; Kotryna Kvederaviciute; Ricardas Tarvydas; Gintare Staniute; Karthik Kalyan; Edita Meskinyte-Kausiliene; Vaidotas Stankevicius; Mindaugas Valius
Journal:  Med Oncol       Date:  2017-01-10       Impact factor: 3.064

2.  A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Authors:  Michael Carducci; Montaser Shaheen; Ben Markman; Sara Hurvitz; Daruka Mahadevan; Dusan Kotasek; Oscar B Goodman; Erik Rasmussen; Vincent Chow; Gloria Juan; Gregory R Friberg; Erick Gamelin; Florian D Vogl; Jayesh Desai
Journal:  Invest New Drugs       Date:  2018-07-07       Impact factor: 3.850

3.  Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Authors:  Zhenjiang Zhao; Guoguo Jin; Ke Yao; Kangdong Liu; Fangfang Liu; Hanyong Chen; Keke Wang; Dhilli Rao Gorja; Kanamata Reddy; Ann M Bode; Zhiping Guo; Zigang Dong
Journal:  Mol Carcinog       Date:  2019-03-01       Impact factor: 4.784

Review 4.  The Relevance of Aurora Kinase Inhibition in Hematological Malignancies.

Authors:  Caio Bezerra Machado; Emerson Lucena DA Silva; Beatriz Maria Dias Nogueira; Jean Breno Silveira DA Silva; Manoel Odorico DE Moraes Filho; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  Cancer Diagn Progn       Date:  2021-07-03

5.  A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhiwei Zhou; Zhixu He; Xinfa Yu; Shufeng Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

6.  Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia.

Authors:  Jorge Antonio Elias Godoy Carlos; Keli Lima; Juan Luiz Coelho-Silva; Raquel de Melo Alves-Paiva; Natália Cestari Moreno; Hugo Passos Vicari; Fábio Pires de Souza Santos; Nelson Hamerschlak; Leticia Veras Costa-Lotufo; Fabiola Traina; João Agostinho Machado-Neto
Journal:  Cell Oncol (Dordr)       Date:  2020-08-28       Impact factor: 6.730

Review 7.  Multi-kinase inhibitors, AURKs and cancer.

Authors:  Jonas Cicenas; Erikas Cicenas
Journal:  Med Oncol       Date:  2016-04-01       Impact factor: 3.064

Review 8.  Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.

Authors:  Meng-Ge Yu; Hu-Yong Zheng
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

Review 9.  Protein Kinase Targets in Breast Cancer.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Int J Mol Sci       Date:  2017-11-27       Impact factor: 5.923

Review 10.  The mechanobiome: a goldmine for cancer therapeutics.

Authors:  Eleana Parajón; Alexandra Surcel; Douglas N Robinson
Journal:  Am J Physiol Cell Physiol       Date:  2020-11-11       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.